Tissue Kallikrein Increases Duration of Survival after Prolonged Coronary Artery Ligation in Hypertensive Rats

Jagdish N. Sharma, S. Atif Abbas, Rajesh P. Shah, Ee-Kiang Gan, A. P. M. Yusof

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There is evidence that the kallikrein-kinin system (KKS) is an important mediator in the regulation of blood pressure, and cardiac and renal hemodynamics. The present study was designed to examine the effect of tissue kallikrein and Trasylol, an inhibitor of tissue kallikrein, on survival time after continuous (prolonged) coronary artery ligation in spontaneously hypertensive rats (SHR). Tissue kallikrein (8 and 16 'g/kg, i.v.) treatment caused significant (p < 0.05) increases in the survival time of SHR as compared with the saline-treated control SHR. Trasylol pretreatment abolished (p < 0.05) the beneficial effect of tissue kallikrein on survival time. The tissue kallikrein treatment resulted in a significant (p < 0.05) reduction in systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) of SHR as compared to the saline-treated control SHR. Trasylol (6 'g/kg) treatment antagonized the effects of tissue kallikrein associated with survival time, SBP, DBP and HR. Ligation of the coronary artery caused a significant (p < 0.001) reduction in the SBP, DBP and HR of SHR, when the mean values were compared between before coronary artery ligation and after coronary artery ligation. However, there was no significant difference (p > 0.05) in SBP, DBP and HR between saline and kallikrein-treated SHR after coronary artery ligation. These findings may suggest that tissue kallikrein is able to act as a cardioprotective agent as demonstrated by an increase in survival time of SHR with prolonged coronary artery ligation.
Original languageEnglish
Pages (from-to)201-205
Number of pages5
JournalPharmacology
Volume70
Issue number4
DOIs
Publication statusPublished - 2004

Fingerprint

Tissue Kallikreins
Ligation
Coronary Vessels
Inbred SHR Rats
Kallikrein-Kinin System
Cardiotonic Agents
Kallikreins
Aprotinin
Hemodynamics
Blood Pressure
Kidney

Cite this

Sharma, Jagdish N. ; Abbas, S. Atif ; Shah, Rajesh P. ; Gan, Ee-Kiang ; Yusof, A. P. M. / Tissue Kallikrein Increases Duration of Survival after Prolonged Coronary Artery Ligation in Hypertensive Rats. In: Pharmacology. 2004 ; Vol. 70, No. 4. pp. 201-205.
@article{f50892b7b6e24867bfeb5b0060e776b1,
title = "Tissue Kallikrein Increases Duration of Survival after Prolonged Coronary Artery Ligation in Hypertensive Rats",
abstract = "There is evidence that the kallikrein-kinin system (KKS) is an important mediator in the regulation of blood pressure, and cardiac and renal hemodynamics. The present study was designed to examine the effect of tissue kallikrein and Trasylol, an inhibitor of tissue kallikrein, on survival time after continuous (prolonged) coronary artery ligation in spontaneously hypertensive rats (SHR). Tissue kallikrein (8 and 16 'g/kg, i.v.) treatment caused significant (p < 0.05) increases in the survival time of SHR as compared with the saline-treated control SHR. Trasylol pretreatment abolished (p < 0.05) the beneficial effect of tissue kallikrein on survival time. The tissue kallikrein treatment resulted in a significant (p < 0.05) reduction in systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) of SHR as compared to the saline-treated control SHR. Trasylol (6 'g/kg) treatment antagonized the effects of tissue kallikrein associated with survival time, SBP, DBP and HR. Ligation of the coronary artery caused a significant (p < 0.001) reduction in the SBP, DBP and HR of SHR, when the mean values were compared between before coronary artery ligation and after coronary artery ligation. However, there was no significant difference (p > 0.05) in SBP, DBP and HR between saline and kallikrein-treated SHR after coronary artery ligation. These findings may suggest that tissue kallikrein is able to act as a cardioprotective agent as demonstrated by an increase in survival time of SHR with prolonged coronary artery ligation.",
keywords = "Blood pressure, Coronary artery ligation, Hypertensive rats, Tissue kallikrein, Trasylol",
author = "Sharma, {Jagdish N.} and Abbas, {S. Atif} and Shah, {Rajesh P.} and Ee-Kiang Gan and Yusof, {A. P. M.}",
note = "Imported on 12 Apr 2017 - DigiTool details were: Journal title (773t) = Pharmacology. ISSNs: 0031-7012;",
year = "2004",
doi = "10.1159/000075549",
language = "English",
volume = "70",
pages = "201--205",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S Karger AG",
number = "4",

}

Tissue Kallikrein Increases Duration of Survival after Prolonged Coronary Artery Ligation in Hypertensive Rats. / Sharma, Jagdish N.; Abbas, S. Atif; Shah, Rajesh P.; Gan, Ee-Kiang; Yusof, A. P. M.

In: Pharmacology, Vol. 70, No. 4, 2004, p. 201-205.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tissue Kallikrein Increases Duration of Survival after Prolonged Coronary Artery Ligation in Hypertensive Rats

AU - Sharma, Jagdish N.

AU - Abbas, S. Atif

AU - Shah, Rajesh P.

AU - Gan, Ee-Kiang

AU - Yusof, A. P. M.

N1 - Imported on 12 Apr 2017 - DigiTool details were: Journal title (773t) = Pharmacology. ISSNs: 0031-7012;

PY - 2004

Y1 - 2004

N2 - There is evidence that the kallikrein-kinin system (KKS) is an important mediator in the regulation of blood pressure, and cardiac and renal hemodynamics. The present study was designed to examine the effect of tissue kallikrein and Trasylol, an inhibitor of tissue kallikrein, on survival time after continuous (prolonged) coronary artery ligation in spontaneously hypertensive rats (SHR). Tissue kallikrein (8 and 16 'g/kg, i.v.) treatment caused significant (p < 0.05) increases in the survival time of SHR as compared with the saline-treated control SHR. Trasylol pretreatment abolished (p < 0.05) the beneficial effect of tissue kallikrein on survival time. The tissue kallikrein treatment resulted in a significant (p < 0.05) reduction in systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) of SHR as compared to the saline-treated control SHR. Trasylol (6 'g/kg) treatment antagonized the effects of tissue kallikrein associated with survival time, SBP, DBP and HR. Ligation of the coronary artery caused a significant (p < 0.001) reduction in the SBP, DBP and HR of SHR, when the mean values were compared between before coronary artery ligation and after coronary artery ligation. However, there was no significant difference (p > 0.05) in SBP, DBP and HR between saline and kallikrein-treated SHR after coronary artery ligation. These findings may suggest that tissue kallikrein is able to act as a cardioprotective agent as demonstrated by an increase in survival time of SHR with prolonged coronary artery ligation.

AB - There is evidence that the kallikrein-kinin system (KKS) is an important mediator in the regulation of blood pressure, and cardiac and renal hemodynamics. The present study was designed to examine the effect of tissue kallikrein and Trasylol, an inhibitor of tissue kallikrein, on survival time after continuous (prolonged) coronary artery ligation in spontaneously hypertensive rats (SHR). Tissue kallikrein (8 and 16 'g/kg, i.v.) treatment caused significant (p < 0.05) increases in the survival time of SHR as compared with the saline-treated control SHR. Trasylol pretreatment abolished (p < 0.05) the beneficial effect of tissue kallikrein on survival time. The tissue kallikrein treatment resulted in a significant (p < 0.05) reduction in systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) of SHR as compared to the saline-treated control SHR. Trasylol (6 'g/kg) treatment antagonized the effects of tissue kallikrein associated with survival time, SBP, DBP and HR. Ligation of the coronary artery caused a significant (p < 0.001) reduction in the SBP, DBP and HR of SHR, when the mean values were compared between before coronary artery ligation and after coronary artery ligation. However, there was no significant difference (p > 0.05) in SBP, DBP and HR between saline and kallikrein-treated SHR after coronary artery ligation. These findings may suggest that tissue kallikrein is able to act as a cardioprotective agent as demonstrated by an increase in survival time of SHR with prolonged coronary artery ligation.

KW - Blood pressure

KW - Coronary artery ligation

KW - Hypertensive rats

KW - Tissue kallikrein

KW - Trasylol

U2 - 10.1159/000075549

DO - 10.1159/000075549

M3 - Article

VL - 70

SP - 201

EP - 205

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 4

ER -